CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
SOHO 最前沿更新与后续问题 | 复发/难治性弥漫大 B 细胞淋巴瘤的序贯治疗：证据、挑战与治愈机会
英文原题：SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence, Challenges, and Opportunities for Cure.
查看英文原题
SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence, Challenges, and Opportunities for Cure.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年间，随着多种新型药物的引入以及双特异性抗体和嵌合抗原受体（CAR）T细胞疗法等免疫疗法的出现，复发/难治性（R/R）弥漫性大B细胞淋巴瘤（DLBCL）的治疗格局迅速演变。随着这些疗法融入常规临床实践，当前的治疗方法越来越依赖于复发时机以及患者特异性因素，如是否符合条件及能否获得CAR-T 细胞治疗。因此，治疗序贯变得日益复杂，现已成为R/R DLBCL管理中的主要挑战。在本综述中，我们总结了为当前治疗策略提供依据的关键临床试验，并讨论了R/R DLBCL中不断演变的治疗序贯方法，旨在优化治愈潜力。
展开英文摘要原文
The therapeutic landscape of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) has rapidly evolved over the past decade with the introduction of multiple novel agents and the emergence of immunotherapies such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. As these therapies become integrated into routine clinical practice, current treatment approaches now increasingly rely on timing of relapse and patient-specific factors such as eligibility and access to CAR T-cell therapy.
Consequently, treatment sequencing has become increasingly complex and now represents a major challenge in the management of R/R DLBCL. In this review, we summarize the pivotal clinical trials that have informed current treatment strategies and discuss evolving approaches to sequencing therapies in R/R DLBCL, with an aim of optimizing curative potential.
论文信息
- 作者
- Wang JF、Salles G、Luttwak E
- 第一作者单位
- Department of Medicine Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY.United States
- 通讯作者单位
- Department of Medicine Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY. Electronic address: luttwake@mskcc.org.United States
- 文献类型
- 综述
- 期刊
- Clinical lymphoma, myeloma & leukemia2026 May
- 原文标识
- PubMed 41826193 · DOI 10.1016/j.clml.2026.02.008